Company news

Delcath Systems, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe

March 1, 2022

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®

February 21, 2022

Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported

February 6, 2022

David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary

January 24, 2022

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

December 1, 2021

Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

November 29, 2021

Delcath Systems Announces Third Quarter 2021 Results

November 8, 2021

Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

November 4, 2021

Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results

October 24, 2021

Delcath Systems Announces Second Quarter 2021 Results

August 9, 2021

Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

August 8, 2021

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

July 27, 2021

Delcath Systems, Inc. Announces First Quarter 2021 Results

May 10, 2021

Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results

April 29, 2021

Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 29, 2021

Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom

April 20, 2021

Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation

March 30, 2021

Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma

March 30, 2021

Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8: 00am Eastern Time

March 30, 2021

Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results

March 23, 2021

Delcath Systems Announces Completion of Underwritten Public Offering

December 10, 2020

Delcath Systems Announces Pricing of Public Offering of Common Stock

December 8, 2020

Delcath Systems Announces Proposed Public Offering of Common Stock

December 7, 2020

Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations

December 6, 2020

Delcath Systems, Inc. Announces Third Quarter 2020 Results

November 10, 2020

Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results

November 1, 2020

Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer

September 30, 2020

Delcath Systems, Inc. Announces Second Quarter 2020 Results

August 12, 2020

Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results

August 5, 2020

Delcath Announces Leadership Transition

May 25, 2020

Delcath Announces First Quarter 2020 Results

May 14, 2020

Delcath Systems Closes $22.0 Million Public Offering of Common Stock

May 4, 2020

Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market

April 30, 2020

Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors

February 18, 2020

Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019

December 18, 2019

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.